Integrin alpha-4 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Integrin alpha-4 shows clinical signal disease relevance led by multiple sclerosis. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P13612. Start with multiple sclerosis, then reuse UniProt P13612 as the stable protein anchor across project notes and exports.
Start with multiple sclerosis, then reuse UniProt P13612 as the stable protein anchor across project notes and exports.
Integrin alpha-4 shows clinical signal disease relevance led by multiple sclerosis. 1 linked drug remains visible in the same block.
Start review with multiple sclerosis because it currently carries clinical signal support. Linked drugs include UCB-1184197. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyIntegrin alpha-4
Review this target as Integrin alpha-4, mapped to UniProt P13612. Sequence length is 1032 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Integrin alpha-4 as ChEMBL target CHEMBL278, mapped to UniProt P13612. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Integrin alpha-4 is the right protein anchor across sources, using UniProt P13612 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why multiple sclerosis is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Integrin alpha-4 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P13612 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Integrin alpha-4 |
| UniProt Accession | P13612 |
| Component Type | Protein |
| Sequence Length | 1032 aa |
Integrin alpha-4
Review this target as Integrin alpha-4, mapped to UniProt P13612. Sequence length is 1032 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Integrin alpha-4 shows clinical signal disease relevance led by multiple sclerosis.
Start review with multiple sclerosis because it currently carries clinical signal support. Linked drugs include UCB-1184197. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL296804 | 10.15 | IC50 | 0.07 | Preclinical |
| CHEMBL502641 | 10.1 | IC50 | 0.08 | Preclinical |
| CHEMBL601470 | 10.1 | IC50 | 0.08 | Preclinical |
| CHEMBL601683 | 10.1 | IC50 | 0.08 | Preclinical |
| CHEMBL448863 | 10.05 | IC50 | 0.09 | Preclinical |
| CHEMBL507665 | 10.05 | IC50 | 0.09 | Preclinical |
| CHEMBL275603 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL445303 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL505992 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL506449 | 9.96 | IC50 | 0.11 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 17 | 126 | 7.1 |
| single protein format | 9 | 30 | 8.9 |
| cell-free format | 2 | 16 | 9.6 |
| tissue-based format | 1 | 7 | 9.2 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 4 | 17 | 6.3 |
| cell-based format | 2 | 3 | 7.7 |